CompletedPhase 2

Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)

United States4 participantsStarted 2002-03

Plain-language summary

Congenital Telangiectasia or Coat's disease is an uncommon disorder that involves the growth of blood vessels of the macula. These blood vessels msy extend beneth the retina to produce an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina which "leak" fluid, causing reduction in vision). Limited forms of treatment are available in managing the neovascularization and its consequences. Anecortave Acetate injection will be considered as an attempt to control the growth of the abnormal blood vessels.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Clinical diagnosis of congenital Telangiectasia (Coat's Disease).
✓. Patients must be 18 years of age or older to receive treatment.
✓. Visual acuity of 20/30 to 20/320 Study Eye on the ETDRS visual acuity chart.
✓. Visual acuity of 20/800 or better Fellow Eye on the ETDRS visual acuity chart.

Exclusion criteria

✕. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
✕. Patients who have undergone intraocular surgery within last 2 months.
✕. Patient participating in any other investigational drug study.
✕. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
✕. Inability to obtain photographs to document CNV (including difficulty with venous access).
✕. Patient with significant liver disease or uremia.
✕. Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
✕. Patient has a history of any medical condition which would preclude scheduled visits or completion of study.

What they're measuring

to investigate the use of anecortave acetate in coats's disease

Timeframe: 24 months

Trial details

NCT IDNCT00211315

SponsorManhattan Eye, Ear & Throat Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Coat's Disease trials